Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  
 449 Diseases   58 Trials   58 Trials   3605 News 


«12...1011121314151617181920...2425»
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment open:  Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) -  Mar 25, 2017   
    P2,  N=15, Recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
    Trial completion, Surgery:  Surgery in Treating Children With Neuroblastoma (clinicaltrials.gov) -  Mar 13, 2017   
    P3,  N=968, Completed, 
    Recruiting --> Suspended Active, not recruiting --> Completed
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Enrollment closed, Trial initiation date:  Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) -  Mar 9, 2017   
    P2,  N=25, Active, not recruiting, 
    Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2015
  • ||||||||||  SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion, Trial primary completion date:  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) -  Feb 27, 2017   
    P1,  N=9, Completed, 
    N=10 --> 2 | Active, not recruiting --> Terminated; Slow Accrual Trial primary completion date: May 2017 --> May 2014 | Active, not recruiting --> Completed
  • ||||||||||  NeuVax (nelipepimut-S) / Dr. Reddy's
    Trial completion, Trial primary completion date:  PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) -  Feb 24, 2017   
    P3,  N=700, Completed, 
    Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 23, 2017   
    P2/3,  N=60, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016 Trial primary completion date: Jan 2017 --> Dec 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial completion, Trial primary completion date, Combination therapy:  Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Feb 17, 2017   
    P2,  N=119, Completed, 
    Trial primary completion date: Jan 2017 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Jan 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial primary completion date, Combination therapy:  Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Feb 3, 2017   
    P2,  N=119, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Enrollment change, Trial termination, Trial primary completion date:  NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) -  Feb 2, 2017   
    P2,  N=3, Terminated, 
    Trial primary completion date: Aug 2017 --> Aug 2018 N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation.
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Jan 30, 2017   
    P1,  N=51, Active, not recruiting, 
    N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation. Trial primary completion date: Jan 2017 --> Jan 2018
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) -  Jan 26, 2017   
    P2,  N=40, Recruiting, 
    Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Nov 2017
  • ||||||||||  ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
    Trial primary completion date, Metastases:  Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) -  Jan 23, 2017   
    P2,  N=53, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Nov 2016 --> Nov 2019 Trial primary completion date: Jan 2017 --> Oct 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
    Trial primary completion date:  Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) -  Jan 4, 2017   
    P2,  N=300, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date, IO biomarker:  The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) -  Jan 4, 2017   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment closed:  Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) -  Dec 28, 2016   
    P2,  N=80, Active, not recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment change, Trial primary completion date:  Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) -  Dec 21, 2016   
    P1,  N=560, Recruiting, 
    Active, not recruiting --> Completed N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial completion, Trial primary completion date:  Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) -  Nov 7, 2016   
    P2,  N=52, Completed, 
    Initiation date: Jan 2017 --> Jul 2017 | Trial primary completion date: Jan 2022 --> Jul 2022 Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Nov 2016
  • ||||||||||  UV1 / Ultimovacs
    Trial primary completion date, Metastases:  A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) -  Nov 7, 2016   
    P1/2,  N=21, Active, not recruiting, 
    Trial primary completion date: Jul 2016 --> Feb 2020 Trial primary completion date: Jul 2015 --> Jul 2020
  • ||||||||||  SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Enrollment closed, Trial primary completion date:  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) -  Nov 2, 2016   
    P1,  N=9, Active, not recruiting, 
    Trial primary completion date: Jul 2015 --> Jul 2020 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017